Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. (0000000047) Μεσογείων 243,, 154 51, Νέο Ψυχικό, 154 51 - voriconazole - ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 40mg/ml - ineof01501 voriconazole 40.000000 mg - voriconazole

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. (0000000047) Μεσογείων 243,, 154 51, Νέο Ψυχικό, 154 51 - voriconazole - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 200mg/tab - ineof01501 voriconazole 200.000000 mg - voriconazole

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. (0000000047) Μεσογείων 243,, 154 51, Νέο Ψυχικό, 154 51 - voriconazole - ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ - 200mg/vial - ineof01501 voriconazole 200.000000 mg - voriconazole

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. (0000000047) Μεσογείων 243,, 154 51, Νέο Ψυχικό, 154 51 - voriconazole - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 50mg/tab - ineof01501 voriconazole 50.000000 mg - voriconazole

Kypros - gresk - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - methotrexate - tablets - 2.5mg - methotrexate (0000059052) 2,5mg - methotrexate

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - methotrexate sodium - inj.so.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΕΣΗ/ΕΓΧΥΣΗ) - 1000mg/40ml - methotrexate sodium 27,419mg - methotrexate

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - methotrexate sodium - tab (ΔΙΣΚΙΟ) - 2,5mg/tab - methotrexate sodium 2,742mg - methotrexate

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium metabisulfite; phenol; water for injections; sulfuric acid; disodium edetate - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted.,note that bacterial cultures should bo obtained before and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. if the organisms are resistant, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, the severity of infection and the important additional concepts discussed in the product information leaflet.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; disodium edetate; sodium hydroxide; sulfuric acid - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

pfizer croatia d.o.o., slavonska avenija 6, zagreb, hrvatska - karboplatin - koncentrat za otopinu za infuziju - 10 mg/ml - urbroj: jedna bočica sa 15 ml koncentrata sadrži 150 mg karboplatina (10 mg/ml)